PRNewswire, 18 September 2020
Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of Nano-X Imaging Ltd. (“Nano-X” or the “Company”) (NASDAQ: NNOX). A complaint has been filed on behalf of investors who purchased the publicly traded securities of Nano-X between August 21, 2020 and September 15, 2020, inclusive (the “Class Period”).
According to the complaint, Nano-X’s securities began trading on the NASDAQ on August 21, 2020.
On September 15, 2020, Citron Research (“Citron”) published a report entitled “Nano-X Imaging (NNOX) A Complete Farce on the Market.” The Citron report described a series of red flags surrounding Nano-X, with Citron ultimately concluding that “this $3 billion company is nothing more than a science project with a simple rendering, minimal R&D, fake customers, no FDA approval, and fraudulent claims that are beyond the realm of possibility.” Nano-X subsequently issued a press release stating, among other things, that “[Nano-X] believes that the allegations in the report are completely without merit.”